证券代码：688488 证券简称：艾迪药业 公告编号：2025-052 经审议，为进一步完善公司治理结构，促进公司规范运作，根据《中华人民 共和国公司法》及《上市公司章程指引》等相关法律法规、规范性文件的规定， 结合公司的实际情况，公司拟不再设置监事会与监事，监事会的职权由董事会审 计委员会行使，同时公司《监事会议事规则》相应废止，公司各项治理制度中涉 及监事会、监事的规定不再适用，并对《公司章程》中相关条款作相应修订。 在公司股东会审议通过取消监事会事项前，公司第三届监事会仍将严格按照 《中华人民共和国公司法》等法律法规和规范性文件的要求，勤勉尽责履行监督 职能，继续对公司经营、公司财务及公司董事、高级管理人员履职的合法合规性 等事项进行监督，维护公司和全体股东的利益。 本议案尚需提交公司股东会审议。 江苏艾迪药业集团股份有限公司 第三届董事会第七次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 江苏艾迪药业集团股份有限公司（以下简称"公司"）第三届董事会第七次 会议通知于 2025 ...

格隆汇9月29日丨艾迪药业(688488.SH)公布，公司于2025年9月28日召开第三届董事会第七次会议和第 三届监事会第七次会议，审议通过了《关于向2025年股票期权激励计划激励对象预留授予部分股票期权 的议案》，确定以2025年9月29日为预留授予日，以人民币13.01元/份的价格向5名预留授予激励对象授 予52.00万份股票期权。 ...

预留授予激励对象名单的核查意见（预留授予日） 江苏艾迪药业集团股份有限公司 监事会关于 2025 年股票期权激励计划 江苏艾迪药业集团股份有限公司（以下简称"公司"） 监事会依据《中华人 民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》 （以下简称"《证券法》"）、《上市公司股权激励管理办法》（以下简称"《管 理办法》"）、《上海证券交易所科创板股票上市规则》（以下简称"《上市规 则》"）、《科创板上市公司自律监管指南第 4 号——股权激励信息披露》等相 关法律、法规及规范性文件和《江苏艾迪药业集团股份有限公司章程》（以下 简称"《公司章程》"）的有关规定，对公司《2025 年股票期权激励计划（草 案）》（以下简称"《激励计划（草案）》"或"本激励计划"）预留授予激励 对象名单（预留授予日）进行了核查，现发表核查意见如下： 1、拟预留授予的激励对象为公司（含子公司）核心技术（业务）骨干人员， 均与公司有聘用或劳动关系。 3、本激励计划预留授予的激励对象未包括公司的独立董事、监事，均符合 《公司法》《证券法》等法律、法规和规范性文件以及《公司章程》规定的任 职资格，符合《管理办法》《上市规则 ...

Market Overview - The biopharmaceutical sector experienced a decline of 0.21% on September 25, with Nossland leading the drop [1] - The Shanghai Composite Index closed at 3853.3, down 0.01%, while the Shenzhen Component Index closed at 13445.9, up 0.67% [1] Stock Performance - Notable gainers in the biopharmaceutical sector included: - Aopu Mai (688293) with a closing price of 62.85, up 7.42% and a trading volume of 30,600 [1] - Rongchang Biotech (688331) closed at 108.50, up 3.43% with a trading volume of 89,200 [1] - Baipusais (301080) closed at 62.16, up 3.43% with a trading volume of 43,500 [1] - Major decliners included: - Nossland (430047) closed at 22.99, down 3.69% with a trading volume of 57,000 [2] - Wufan Biotech (301393) closed at 53.12, down 3.42% with a trading volume of 24,600 [2] - Kexing Pharmaceutical (688136) closed at 38.75, down 3.34% with a trading volume of 53,500 [2] Capital Flow - The biopharmaceutical sector saw a net outflow of 207 million yuan from institutional investors, while retail investors contributed a net inflow of 45.07 million yuan [2] - Notable capital flows included: - Rongchang Biotech (688331) with a net inflow of 1.021 billion yuan from institutional investors [3] - Junshi Biosciences (688180) with a net inflow of 35.36 million yuan from institutional investors [3] - Aopu Mai (688293) with a net inflow of 9.41 million yuan from institutional investors [3]

Market Overview - On September 24, the biopharmaceutical sector rose by 0.09% compared to the previous trading day, with Ganli Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3853.64, up 0.83%, while the Shenzhen Component Index closed at 13356.14, up 1.8% [1] Individual Stock Performance - Ganli Pharmaceutical (603087) closed at 79.34, with a significant increase of 10.00% and a trading volume of 343,300 shares, resulting in a transaction value of 2.696 billion yuan [1] - Other notable performers included: - Sanofi (688336) at 55.98, up 5.11% with a transaction value of 431 million yuan [1] - Aidi Pharmaceutical (688488) at 15.26, up 4.88% with a transaction value of 174 million yuan [1] - Nuoviz (688105) at 22.65, up 4.47% with a transaction value of 91.03 million yuan [1] Capital Flow Analysis - The biopharmaceutical sector saw a net inflow of 86.36 million yuan from institutional investors, while retail investors experienced a net outflow of 69.34 million yuan [2] - The capital flow for individual stocks showed that Ganli Pharmaceutical had a net inflow of 14.4 million yuan from institutional investors, but a net outflow of 85.14 million yuan from retail investors [3] - Changchun High-tech (000661) had a net inflow of 43.56 million yuan from institutional investors, while retail investors faced a net outflow of 88.37 million yuan [3]

Core Insights - Eddie Pharmaceuticals' stock price increased by 2.20% on September 24, reaching 14.87 CNY per share, with a market capitalization of 6.257 billion CNY [1] - The company has seen a year-to-date stock price increase of 89.19%, but has experienced a decline of 2.11% over the last five trading days and 11.86% over the last twenty days [1] - For the first half of 2025, Eddie Pharmaceuticals reported a revenue of 362 million CNY, representing a year-on-year growth of 100.19%, and a net profit of 9.191 million CNY, up 120.23% year-on-year [2] Company Overview - Eddie Pharmaceuticals, established on December 15, 2009, and listed on July 20, 2020, is based in Yangzhou, Jiangsu Province [1] - The company's main business involves the exploration, research, and sales of innovative chemical drugs and human-derived protein products, with revenue composition as follows: human-derived protein 41.11%, new drugs 35.69%, diagnostic equipment and reagents 13.62%, generic drugs 9.47%, and others 0.11% [1] - As of June 30, 2025, the number of shareholders increased by 34.45% to 11,900, while the average circulating shares per person decreased by 25.62% to 35,247 shares [2] Financial Performance - Since its A-share listing, Eddie Pharmaceuticals has distributed a total of 20.16 million CNY in dividends, with no dividends paid in the last three years [3] - As of June 30, 2025, the top ten circulating shareholders include Penghua Medical Technology Stock A and new entrants such as招商行业精选股票 and 广发价值核心混合A, indicating a shift in institutional holdings [3]

Group 1 - The core point of the news is that Aidi Pharmaceutical's stock price dropped by 5.03% to 14.74 CNY per share, with a total market capitalization of 6.202 billion CNY as of the report date [1] - Aidi Pharmaceutical, established on December 15, 2009, and listed on July 20, 2020, is based in Yangzhou, Jiangsu Province, and focuses on the exploration, research, and sales of innovative chemical drugs and human-derived protein products [1] - The company's revenue composition includes human-derived proteins at 41.11%, new drugs at 35.69%, diagnostic equipment, reagents, and others at 13.62%, generic drugs at 9.47%, and other supplementary products at 0.11% [1] Group 2 - Among Aidi Pharmaceutical's top ten circulating shareholders, one fund from GF Fund Management, the GF Value Core Mixed A (010377), entered the top ten in the second quarter, holding 3.931 million shares, which is 0.93% of the circulating shares [2] - The GF Value Core Mixed A fund, established on January 22, 2021, has a latest scale of 3.516 billion CNY, with a year-to-date return of 62.56% and a one-year return of 110.84% [2] - The fund manager, Wu Yuanyi, has been in position for nearly 4 years, with the fund's total asset scale at 20.478 billion CNY and a best return of 112.4% during his tenure [3]

Group 1 - The core viewpoint of the news is that Eddy Pharmaceutical has seen a 5% increase in stock price, reaching 15.95 CNY per share, with a total market capitalization of 6.711 billion CNY [1] - Eddy Pharmaceutical, established on December 15, 2009, and listed on July 20, 2020, focuses on the exploration, research, and sales of innovative chemical drugs and human-derived protein products [1] - The revenue composition of Eddy Pharmaceutical includes human-derived proteins at 41.11%, new drugs at 35.69%, diagnostic equipment and reagents at 13.62%, generic drugs at 9.47%, and other supplementary products at 0.11% [1] Group 2 - According to data, the Guotou Ruijin Fund has a significant holding in Eddy Pharmaceutical, with the Guotou Ruijin Specialized and New Quantitative Stock Selection Mixed A Fund (015842) holding 76,300 shares, accounting for 1.39% of the fund's net value [2] - The Guotou Ruijin Specialized and New Quantitative Stock Selection Mixed A Fund has achieved a year-to-date return of 51.3% and a one-year return of 113.06%, ranking 894 out of 8172 and 352 out of 7980 in its category, respectively [2] - The fund manager, Zhao Jian, has been in position for nearly 12 years, with the fund's total asset size at 3.848 billion CNY and a best return of 172.91% during his tenure [3]

Core Insights - The innovation drug industry in China is experiencing significant advancements in product research and development, with companies actively discussing their progress and strategies during the recent performance briefing session [1][2][3]. Group 1: Product Innovation and R&D Progress - Companies like Fudan Zhangjiang and Olin Bio are making notable advancements in their product pipelines, focusing on photodynamic therapy and vaccines for "super bacteria" [1][2]. - Fudan Zhangjiang is developing several drugs targeting conditions such as severe acne and bladder cancer, with ongoing clinical studies [2]. - Olin Bio is researching multiple vaccines for "super bacteria," aiming to initiate clinical trials for flu vaccines by mid-2025 [2]. Group 2: Business Expansion and Market Strategy - Companies are planning to expand their production capacity to support product commercialization, with Baiyao Tai focusing on launching several products that have completed Phase III clinical trials [3][4]. - Shian Bio is set to contribute significant revenue from its various vaccine products, including those for swine fever and other diseases [4]. Group 3: Internationalization and Market Entry - The trend of "going global" is a major focus for the domestic biopharmaceutical industry, with companies exploring diverse international pathways [5]. - Yuantong Bio is awaiting FDA approval for its naloxone nasal spray, marking a step towards international market entry [5]. - Aidi Pharmaceutical has received regulatory approval for its HIV treatment in Zanzibar, highlighting its international expansion efforts [6]. - Companies like Ailis and Haichuang Pharmaceutical are actively pursuing overseas partnerships and clinical trials to enhance their global presence [6][7].

Market Overview - The biopharmaceutical sector experienced a decline of 0.41% on September 16, with Aidi Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3861.87, up 0.04%, while the Shenzhen Component Index closed at 13063.97, up 0.45% [1] Individual Stock Performance - Notable declines in individual stocks include: - Wenchang Pharmaceutical (688488) down 3.29% to 14.99 - Wanze Shares (000534) down 2.54% to 16.10 - Changchun High-tech (000661) down 2.33% to 123.85 - Nossland (430047) down 2.16% to 25.82 - Sangh Bio (688336) down 2.12% to 53.55 [1] Capital Flow Analysis - The biopharmaceutical sector saw a net outflow of 708 million yuan from institutional investors, while retail investors contributed a net inflow of 446 million yuan [3] - Key capital flows for selected stocks include: - Kangchen Pharmaceutical (603590) with a net inflow of 20.01 million yuan from institutional investors - ST Weiming (002581) showing a significant net inflow of 3.73 million yuan from retail investors [3]